MedTrace Logo

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

NCT07226349 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2026-05-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

BG-75098

Administered orally.

DRUG

BGB-43395

Administered orally.

DRUG

Fulvestrant

Administered by intramuscular injection.

Sponsors & Collaborators

  • BeOne Medicines

    lead INDUSTRY

Principal Investigators

  • Study Director · BeOne Medicines

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-11
Primary Completion
2028-11-01
Completion
2028-11-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07226349 on ClinicalTrials.gov